Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the appointment ...

We present an unusual case of acute bilateral hearing loss as the initial manifestation ... The physical exam revealed no focal neurological deficits, dysmetria, ataxia or cranial nerve abnormalities.

IgG MoDE Degraders: BHV-1300 Phase 1 completing last remaining dose cohorts with the optimized subcutaneous formulation with expected completion in 1H 2025. BHV-1310 first-in-human study anticipated ...

T he way people with disabilities are treated is backsliding in the U.S., advocates say. Cruel names are slung around without ...

*The actual case names have been changed for client confidentiality. Settlement amounts are all inclusive amounts (inclusive ...

Interferon gamma-1b is under clinical development by Amgen and currently in Phase II for Myelodysplastic Syndrome.

According to GlobalData, Phase II drugs for Spinocerebellar Ataxia (SCA) have a 29% phase transition success ... It was also under the development of Alzheimer's disease, acute on chronic liver ...

Hypermobility of joints, joint instability, and acute conditions, such as arthritis ... brain injury or multiple sclerosis. Ataxia Lack of co-ordination of muscle movements due to a neurological ...

commenting on the striking symmetry of the ophthalmoplegia and the severity of the ataxia.3 One patient was also drowsy during the acute phase of the illness. The presence of areflexia and neuropathy ...

These involuntary movements are unusual during or after acute stroke. Three varieties of alien hand syndrome ... She made no attempt to correct the movements visually at the onset of the process.

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.